Jackson Center -
Advocated by
The bill is named for
A recently initiated study of Halberd's patented drug, LDN+, involves pre-pilot studies with military veterans to evaluate the drug's safety and its effectiveness in treating pain and anxiety associated with PTSD, Suicide Ideation and chemical/alcohol addiction.
As previously reported relative to PTSD/suicide treatment and prevention, Halberd's patent-pending nasal spray is uniquely designed to mitigate the cascade of inflammatory neurotransmitters which can lead to PTSD and suicide ideation. The nasal spray recently successfully concluded Phase 1 animal testing at
Both Halberd products are being proposed to the military for future consideration in light of the passage of this important House bill.
To stay updated on the latest developments from Halberd, subscribe by submitting this form. (https://halberdcorporation.com/contact-us/)
Contact:
Email: w.hartman@halberdcorporation.com
Web: www.halberdcorporation.com
About
Safe Harbor Notice
Certain statements contained herein are 'forward-looking statements' (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results.
(C) 2024 Electronic News Publishing, source